林业发展局批准Novavax在安全审查后恢复对COVID-19和流感混合疫苗的试验。 FDA clears Novavax to resume trials for combined COVID-19 and flu vaccine after safety review.
美国食品和药物管理局已取消诺瓦克斯联合COVID-19和流感疫苗及其独立流感疫苗的临床禁用. The FDA has lifted the clinical hold on Novavax's combination COVID-19 and influenza vaccine and its standalone flu vaccine. 扣留是在一名参与者患有运动性神经病症状后,但林业发展局确定这些症状与疫苗无关。 The hold was placed after a participant experienced motor neuropathy symptoms, but the FDA determined these symptoms were unrelated to the vaccine. Novavax计划恢复第三阶段试验,该公司的股票价格根据林业发展局的决定上涨13%以上。 Novavax plans to resume its Phase 3 trial, and the company's stock price increased by over 13% in response to the FDA's decision.